Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation

por Oslob, Johan D., Johnson, Russell J., Cai, Haiying, Feng, Shirley Q., Hu, Lily, Kosaka, Yuko, Lai, Julie, Sivaraja, Mohanram, Tep, Samnang, Yang, Hanbiao, Zaharia, Cristiana A., Evanchik, Marc J., McDowell, Robert S.
Publicado em 2012

Reversible covalent direct thrombin inhibitors

por Sivaraja, Mohanram, Pozzi, Nicola, Rienzo, Matthew, Lin, Kenneth, Shiau, Timothy P., Clemens, Daniel M., Igoudin, Lev, Zalicki, Piotr, Chang, Stephanie S., Estiarte, M. Angels, Short, Kevin M., Williams, David C., Datta, Anirban, Di Cera, Enrico, Kita, David B.
Publicado no PLoS One (2018)

VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis

por Sivaraja, Mohanram, Clemens, Daniel M., Sizikov, Sivan, Dash, Subhadra, Xu, Chengpei, Rienzo, Matthew, Yang, Bo, Ryan, Molly, Chattopadhyay, Madhuri, Igoudin, Lev, Chang, Stephanie S., Keutzer, Samuel, Zalicki, Piotr, Estiarte, M. Angels, Shiau, Timothy P., Short, Kevin M., Williams, David C., Datta, Anirban, Pozzi, Nicola, Di Cera, Enrico, Gibson, C. Michael, Fox, Keith A.A., Kita, David B.
Publicado no Thromb Res (2020)